You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novo Nordisk’s ziltivekimab hits primary endpoint in CKD trial

Novo Nordisk’s investigational interleukin-6 (IL-6) inhibitor ziltivekimab met the primary endpoint in a Phase II trial in people with advanced chronic kidney disease (CKD) and elevated high-sensitivity C-reactive protein (hsCRP), representing high cardiovascular risk.